ClinicalTrials.gg
TerminatedNCT02722304Updated May 13, 2021Results posted

Stage 1 Study of ARALAST NP and GLASSIA in A1PI Deficiency

A Phase 3 interventional study of ARALAST NP 60 mg/kg and ARALAST NP 120 mg/kg in Chronic Obstructive Pulmonary Disease and Alpha1-antitrypsin Deficiency, sponsored by Baxalta now part of Shire. Terminated at 17 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-05-13.

Sponsored by Baxalta now part of Shire (part of Takeda) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
7
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,278 studies in Pulmonary Disease, Chronic Obstructive with a site in United States — 137 open to participants now, 172 under way, 20 of them phase 3. Pulmonary Disease, Chronic Obstructive · United States.

Enrollment
958th of 1,037
7 · median 100
Started
2016
with 56 others
Phase 3
226 of 1,278
16 open now
Registered
714th of 1,278
by date

Among the 1,278 studies in Pulmonary Disease, Chronic Obstructive with a site in United States, this one is the 958th largest by enrollment of the 1,037 interventional ones that give a count, is one of 57 that started in 2016, is one of 226 in phase 3, and was the 714th registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

137 of the 1,278 studies in Pulmonary Disease, Chronic Obstructive with a site in United States are open now. Recruiting first, the newest first:

132 more — sign in →

All 137 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,278 studies in Pulmonary Disease, Chronic Obstructive with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to conduct a pilot study to evaluate the safety and efficacy of weekly administration of Alpha1-Proteinase Inhibitor (A1PI) augmentation therapy in subjects with A1PI deficiency and emphysema/ chronic obstructive pulmonary disease (COPD).

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease
  • Alpha1-antitrypsin Deficiency
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. ≥18 years of age at the time of screening
  2. Endogenous plasma Alpha1-Proteinase Inhibitor (A1PI) level \<8 μM at any time during the Screening period for treatment-naïve participants, or following 4-weeks minimum from previous augmentation therapy in treatment-experienced participants. The screening plasma A1PI level may be repeated if a participant obtains an exclusionary value that is suspected to be due to inadequate washout of A1PI).
  3. Participant has documented A1PI genotype of Pi*Z/Z, Pi*Z/Null, Pi*Malton/Z, Pi*Null/Null, or other rare genotypes (except PI*MS, PI*MZ, or PI*SZ).
  4. Clinically evident mild-moderate (COPD) (according to GOLD criteria for diagnosis) at the time of screening.
  5. If the participant is treated with any respiratory medications including inhaled bronchodilators, inhaled , or systemic corticosteroids (e.g. prednisone ≤ 10 mg/day or its equivalent), the doses of the participant's medications have remained stable for at least 28 days prior to screening.
  6. No abnormalities (other than emphysema, bronchitis or bronchiectasis) detected via a chest computed tomography (CT) or chest X-ray at the time of screening.
  7. If female of , participant must have a negative pregnancy test at screening and agree to employ adequate measures for the duration of the study.
  8. Participant is willing and able to comply with the requirements of the protocol.

Exclusion criteria

Exclusion Criteria:

  1. Known ongoing or history of pulmonary impairment other than emphysema/ .
  2. The participant is experiencing lower respiratory infection (LRTI)/acute pulmonary exacerbation (APE) at the time of enrollment (signing form (ICF)). Participant may be rescreened after both clinical resolution of LRTI/APE and having also remained stable for at least 4 weeks after the end of LRTI/APE).
  3. Known ongoing or history of cor pulmonale.
  4. Known resting partial pressure of carbon dioxide (PaCO2) levels of > 45 mmHg.
  5. Clinically significant congestive heart failure with (NYHA) Class III/IV symptoms.
  6. The participant has received an organ transplant, has undergone major lung surgery, or is currently on a transplant list.
  7. Known history of ongoing (other than adequately treated basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix).
  8. Smoker or participant that has ceased smoking for less than one year prior to screening whose levels of cotinine are outside of the normal range of a nonsmoker.

    All participants must agree to refrain from smoking throughout the course of the study.

  9. The participant is receiving long-term therapy (> 28 days) of parenteral or oral corticosteroids at doses greater than 10 mg/day of prednisone or its equivalent).
  10. The participant is receiving long-term round-the-clock oxygen supplementation (other than temporary for acute COPD exacerbation, or supplemental oxygen (O2) with continuous positive airway pressure [CPAP], or bi-level positive airway pressure [BiPAP] during the day).
  11. Participant has for CT (e.g. body weight and/or body size exceeding the weight and gantry size limits specified by the manufacturer of the CT scanner, inability to lie flat in the CT scanner, claustrophobia, metal prosthesis or pacemaker in the chest wall or upper extremity that would impact lung density assessment).
  12. Participant is unwilling or unable to modify bronchodilator medications for 6 hours for short acting β2 agonists, 24 hours for long-acting β2 agonists, and 48 hours for long acting anticholinergics prior to the scheduled quantitative CT scan.
  13. Known severe immunoglobulin A (IgA) deficiency (ie, IgA level \< 8 mg/dL at screening).
  14. Known history of following infusions of human blood or blood components (eg, human immunoglobulins or human albumin).
  15. Presence of clinically significant laboratory abnormalities at the screening
  16. The participant has a clinically significant medical, psychiatric, or cognitive illness, is a recreational drug/alcohol user, or has any other uncontrolled medical condition (eg, unstable angina, , uncontrolled hypertension) that, in the opinion of the investigator, would affect participant's safety or compliance or confound the results of the study.
  17. Participant has been exposed to another IP within 28 days prior to enrollment or is scheduled to participate in another clinical study involving an IP or device during the course of this study.
  18. Participant is a family member or employee of the investigator.
  19. If female, participant is pregnant or nursing at the time of enrollment.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
7 participants (actual)

Study arms

  • Experimental
    ARALAST NP 60 mg/kg

    60 mg/kg body weight/week

    Biological: ARALAST NP 60 mg/kg

  • Experimental
    ARALAST NP 120 mg/kg

    120 mg/kg body weight/week

    Biological: ARALAST NP 120 mg/kg

  • Experimental
    GLASSIA 60 mg/kg

    60 mg/kg body weight/week

    Biological: GLASSIA 60 mg/kg

  • Experimental
    GLASSIA 120 mg/kg

    120 mg/kg body weight/week

    Biological: GLASSIA 120 mg/kg

  • Placebo comparator
    Placebo

    Human Albumin 2%

    Biological: Human Albumin 2%

Interventions

  • BiologicalARALAST NP 60 mg/kg

    Drug page: Alpha 1-Antitrypsin

    ARALAST NP is an Alpha1-Proteinase Inhibitor (A1PI) augmentation therapy

    Also known as: Alpha1-Proteinase Inhibitor (Human), A1PI, Alpha1-Proteinase Inhibitor

  • BiologicalARALAST NP 120 mg/kg

    Drug page: Alpha 1-Antitrypsin

    ARALAST NP is an Alpha1-Proteinase Inhibitor (A1PI) augmentation therapy

    Also known as: Alpha1-Proteinase Inhibitor, Alpha1-Proteinase Inhibitor (Human), A1PI

  • BiologicalGLASSIA 60 mg/kg

    Drug page: Alpha 1-Antitrypsin

    GLASSIA is an Alpha1-Proteinase Inhibitor (A1PI) augmentation therapy

    Also known as: Alpha1-Proteinase Inhibitor (Human), A1PI, Alpha1-Proteinase Inhibitor

  • BiologicalGLASSIA 120 mg/kg

    Drug page: Alpha 1-Antitrypsin

    GLASSIA is an Alpha1-Proteinase Inhibitor (A1PI) augmentation therapy

    Also known as: Alpha1-Proteinase Inhibitor, Alpha1-Proteinase Inhibitor (Human), A1PI

  • BiologicalHuman Albumin 2%

    Human albumin 2% (by appropriate dilution with normal saline solution)

06

What researchers measure

Primary outcomes

  1. Rate of Change in Lung Density Based on Group 1 (ARALAST NP) Versus Placebo, Group 3 and Group 4 (GLASSIA) Versus Placebo

    Rate of change in lung density was assessed by computed tomography (CT) densitometry. Computed Tomography (CT) scans was used to measure lung density as a quantitative assessment of emphysema progression and treatment efficacy at each of the study visits. CT lung density at the 15th percentile (PD15) is the threshold below which 15% of the voxels have lower densities, and was used as the parameter for estimating the rate of lung density decline. Rate of change in lung density based on Group 1 (ARALAST NP) versus Placebo, Group 3 and Group 4 (GLASSIA) versus Placebo were reported. The safety analysis set used for all the efficacy parameter assessment.

    Time frame: Baseline, Early termination of the study (approximately 22 months)

Secondary outcomes

  1. Rate of Change in Lung Density for Each Treatment Group

    Rate of change in lung density was assessed by computed tomography (CT) densitometry for each treatment group. Computed Tomography (CT) scans was used to measure lung density as a quantitative assessment of emphysema progression and treatment efficacy at each of the study visits. The safety analysis set used for all the efficacy parameter assessment.

    Time frame: Baseline, Early termination of the study (approximately 22 months)

  2. Mean Steady State Trough Concentration of Antigenic and Functional Alpha1-Proteinase Inhibitor (A1PI) for ARALAST NP and GLASSIA at Each Dose Level

    Mean steady state trough concentration of antigenic and functional alpha1-proteinase inhibitor (a1pi) for ARALAST NP and GLASSIA at each dose level was reported.

    Time frame: Baseline, Early termination of the study (approximately 22 months)

  3. Number of Events With Related and Unrelated Serious and Non-Serious Treatment Emergent Adverse Event (TEAE)

    An Adverse event (AE) was defined as any untoward medical occurrence in a participant administered an IP that does not necessarily have a causal relationship with the treatment. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged in-patient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. TEAEs were defined as AEs with a start date on or after the first dose of double-blind investigational product or a start date before the date of the first dose of double-blind investigational product that increased in severity or after the date of the first dose. TEAE related to Investigational Product (IP) and Study Procedures (SP) were considered. A non-serious AE is an AE that does not meet the criteria of an SAE. Number of events with related and unrelated serious and non-serious TEAE were reported.

    Time frame: From start of study treatment up to early termination of the study (approximately 22 months)

  4. Percentage of Participants With Related and Unrelated Serious and Non-Serious Treatment Emergent Adverse Events (TEAE's)

    An Adverse event (AE) was defined as any untoward medical occurrence in a participant administered an IP that does not necessarily have a causal relationship with the treatment. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged in-patient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. TEAEs were defined as AEs with a start date on or after the first dose of double-blind investigational product or a start date before the date of the first dose of double-blind investigational product that increased in severity or after the date of the first dose. A non-serious AE is an AE that does not meet the criteria of an SAE. TEAE related to IP and Study Procedures were considered. Percentage of participants with related and unrelated serious and non-serious TEAE were reported.

    Time frame: From start of study treatment up to early termination of the study (approximately 22 months)

  5. Number of Events With Temporally Related Serious and Non-Serious Treatment Emergent Adverse Events (AEs)

    An Adverse event (AE) was defined as any untoward medical occurrence in a participant administered an IP that does not necessarily have a causal relationship with the treatment. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged in-patient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. TEAEs were defined as AEs with a start date on or after the first dose of double-blind investigational product or a start date before the date of the first dose of double-blind investigational product that increased in severity or after the date of the first dose. A non-serious AE is an AE that does not meet the criteria of an SAE. TEAEs were temporally related to treatment administration (ie, occurred within 72 hours following the end of the infusion). TEAE Related to IP were considered.

    Time frame: From start of study treatment up to early termination of the study (approximately 22 months)

  6. Percentage of Participants With Temporally Related Serious and Non-Serious Treatment Emergent Adverse Events (AEs)

    An Adverse event (AE) was defined as any untoward medical occurrence in a participant administered an IP that does not necessarily have a causal relationship with the treatment. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged in-patient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. TEAEs were defined as AEs with a start date on or after the first dose of double-blind investigational product or a start date before the date of the first dose of double-blind investigational product that increased in severity or after the date of the first dose. A non-serious AE is an AE that does not meet the criteria of an SAE. TEAEs were temporally related to treatment administration (ie, occurred within 72 hours following the end of the infusion). TEAE Related to IP were considered.

    Time frame: From start of study treatment up to early termination of the study (approximately 22 months)

  7. Number of Events With Suspected Adverse Reactions or Serious and Non-Serious Adverse Reactions (ARs)

    An Adverse Reactions (ARs) plus suspected adverse reaction is any adverse event which met any of the following criteria: an adverse event that began during infusion or within 72 hours following the end of IP infusion; an adverse event considered by either the investigator and/or the sponsor to be possibly or probably related to IP administration; an adverse event for which causality assessment was missing or indeterminate. Adverse reaction included both serious and non-serious ARs.

    Time frame: From start of study treatment up to early termination of the study (approximately 22 months)

  8. Percentage of Participants With Suspected Adverse Reactions or Serious and Non-Serious Adverse Reactions (ARs)

    An Adverse Reactions (AR) plus suspected adverse reaction is any adverse event which met any of the following criteria: an adverse event that began during infusion or within 72 hours following the end of IP infusion; an adverse event considered by either the investigator and/or the sponsor to be possibly or probably related to IP administration; an adverse event for which causality assessment was missing or indeterminate. Adverse reaction included both serious and non-serious ARs.

    Time frame: From start of study treatment up to early termination of the study (approximately 22 months)

  9. Percentage of Participants With at Least One Infusion Rate Change or Infusion Interruption or Stopped Due to AEs

    An Adverse event (AE) was defined as any untoward medical occurrence in a participant administered an IP that does not necessarily have a causal relationship with the treatment. Number of infusions for which the infusion rate was reduced and/or the infusion interrupted or stopped due to adverse events (AEs) were reported.

    Time frame: From start of study treatment up to early termination of the study (approximately 22 months)

  10. Number of Participants Who Developed Anti-A1PI Antibodies Following Treatment With ARALAST NP or GLASSIA

    Number of participants who developed anti- A1PI antibodies following treatment with ARALAST NP or GLASSIA were reported. Anti-A1PI binding antibody were determined for the samples that tested positive or negative at each assessment time point.

    Time frame: Baseline, Early termination of the study (approximately 22 months)

07

Results

Posted Oct 8, 2019
Limitations and caveats
The Data Monitoring Committee (DMC) reviewed the available efficacy and safety data and unanimously recommended to terminate the study. The decision was based on the very low number of enrollees, and the slow rate of participant enrollment.

Participant flow

The study was conducted at 4 study centers in the United States (3) and Australia (1) between 02 November 2016 (first participant first visit) and 14 September 2018 (last participant last visit).

Participant flow — Overall Study
MilestoneARALAST NP 60 mg/kg (Group 1)ARALAST NP 120 mg/kg (Group 2)GLASSIA 60 mg/kg (Group 3)GLASSIA 120 mg/kg (Group 4)Placebo (Group 5)
Started10222
Treated10112
Completed00000
Not completed10222
Withdrew: Study terminated by sponsor10211
Withdrew: Other00011

Outcome measures

PrimaryRate of Change in Lung Density Based on Group 1 (ARALAST NP) Versus Placebo, Group 3 and Group 4 (GLASSIA) Versus Placebo

Rate of change in lung density was assessed by computed tomography (CT) densitometry. Computed Tomography (CT) scans was used to measure lung density as a quantitative assessment of emphysema progression and treatment efficacy at each of the study visits. CT lung density at the 15th percentile (PD15) is the threshold below which 15% of the voxels have lower densities, and was used as the parameter for estimating the rate of lung density decline. Rate of change in lung density based on Group 1 (ARALAST NP) versus Placebo, Group 3 and Group 4 (GLASSIA) versus Placebo were reported. The safety analysis set used for all the efficacy parameter assessment.

Time frame:
Baseline, Early termination of the study (approximately 22 months)

No measurements were reported for this outcome.

SecondaryRate of Change in Lung Density for Each Treatment Group

Rate of change in lung density was assessed by computed tomography (CT) densitometry for each treatment group. Computed Tomography (CT) scans was used to measure lung density as a quantitative assessment of emphysema progression and treatment efficacy at each of the study visits. The safety analysis set used for all the efficacy parameter assessment.

Time frame:
Baseline, Early termination of the study (approximately 22 months)

No measurements were reported for this outcome.

SecondaryMean Steady State Trough Concentration of Antigenic and Functional Alpha1-Proteinase Inhibitor (A1PI) for ARALAST NP and GLASSIA at Each Dose Level

Mean steady state trough concentration of antigenic and functional alpha1-proteinase inhibitor (a1pi) for ARALAST NP and GLASSIA at each dose level was reported.

Time frame:
Baseline, Early termination of the study (approximately 22 months)

No measurements were reported for this outcome.

SecondaryNumber of Events With Related and Unrelated Serious and Non-Serious Treatment Emergent Adverse Event (TEAE)

An Adverse event (AE) was defined as any untoward medical occurrence in a participant administered an IP that does not necessarily have a causal relationship with the treatment. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged in-patient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. TEAEs were defined as AEs with a start date on or after the first dose of double-blind investigational product or a start date before the date of the first dose of double-blind investigational product that increased in severity or after the date of the first dose. TEAE related to Investigational Product (IP) and Study Procedures (SP) were considered. A non-serious AE is an AE that does not meet the criteria of an SAE. Number of events with related and unrelated serious and non-serious TEAE were reported.

Time frame:
From start of study treatment up to early termination of the study (approximately 22 months)
Reported as:
Number · Events
Number of Events With Related and Unrelated Serious and Non-Serious Treatment Emergent Adverse Event (TEAE)
EventsARALAST NP 60 mg/kg (Group 1)GLASSIA 60 mg/kg (Group 3)GLASSIA 120 mg/kg (Group 4)Placebo (Group 5)
Serious TEAE: Events Related to IP0000
Non-serious TEAE: Events Related to IP00019
Serious TEAE: Events Related to SP0000
Non-serious TEAE: Events Related to SP0001
Serious TEAE: Unrelated Events0000
Non-serious TEAE: Unrelated Events2005
SecondaryPercentage of Participants With Related and Unrelated Serious and Non-Serious Treatment Emergent Adverse Events (TEAE's)

An Adverse event (AE) was defined as any untoward medical occurrence in a participant administered an IP that does not necessarily have a causal relationship with the treatment. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged in-patient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. TEAEs were defined as AEs with a start date on or after the first dose of double-blind investigational product or a start date before the date of the first dose of double-blind investigational product that increased in severity or after the date of the first dose. A non-serious AE is an AE that does not meet the criteria of an SAE. TEAE related to IP and Study Procedures were considered. Percentage of participants with related and unrelated serious and non-serious TEAE were reported.

Time frame:
From start of study treatment up to early termination of the study (approximately 22 months)
Reported as:
Number · Percentage of Participants
Percentage of Participants With Related and Unrelated Serious and Non-Serious Treatment Emergent Adverse Events (TEAE's)
Percentage of ParticipantsARALAST NP 60 mg/kg (Group 1)GLASSIA 60 mg/kg (Group 3)GLASSIA 120 mg/kg (Group 4)Placebo (Group 5)
Serious TEAE: Related to IP0000
Non-Serious TEAE: Related to IP00050
Serious TEAE: Related to SP0000
Non-Serious TEAE: Related to SP00050
Serious TEAE: Unrelated0000
Non-Serious TEAE: Unrelated10000100
SecondaryNumber of Events With Temporally Related Serious and Non-Serious Treatment Emergent Adverse Events (AEs)

An Adverse event (AE) was defined as any untoward medical occurrence in a participant administered an IP that does not necessarily have a causal relationship with the treatment. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged in-patient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. TEAEs were defined as AEs with a start date on or after the first dose of double-blind investigational product or a start date before the date of the first dose of double-blind investigational product that increased in severity or after the date of the first dose. A non-serious AE is an AE that does not meet the criteria of an SAE. TEAEs were temporally related to treatment administration (ie, occurred within 72 hours following the end of the infusion). TEAE Related to IP were considered.

Time frame:
From start of study treatment up to early termination of the study (approximately 22 months)
Reported as:
Number · Events
Number of Events With Temporally Related Serious and Non-Serious Treatment Emergent Adverse Events (AEs)
EventsARALAST NP 60 mg/kg (Group 1)GLASSIA 60 mg/kg (Group 3)GLASSIA 120 mg/kg (Group 4)Placebo (Group 5)
Temporally Serious TEAE Related to IP0000
Temporally Non-Serious TEAE Related to IP00017
SecondaryPercentage of Participants With Temporally Related Serious and Non-Serious Treatment Emergent Adverse Events (AEs)

An Adverse event (AE) was defined as any untoward medical occurrence in a participant administered an IP that does not necessarily have a causal relationship with the treatment. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged in-patient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. TEAEs were defined as AEs with a start date on or after the first dose of double-blind investigational product or a start date before the date of the first dose of double-blind investigational product that increased in severity or after the date of the first dose. A non-serious AE is an AE that does not meet the criteria of an SAE. TEAEs were temporally related to treatment administration (ie, occurred within 72 hours following the end of the infusion). TEAE Related to IP were considered.

Time frame:
From start of study treatment up to early termination of the study (approximately 22 months)
Reported as:
Number · Percentage of Participants
Percentage of Participants With Temporally Related Serious and Non-Serious Treatment Emergent Adverse Events (AEs)
Percentage of ParticipantsARALAST NP 60 mg/kg (Group 1)GLASSIA 60 mg/kg (Group 3)GLASSIA 120 mg/kg (Group 4)Placebo (Group 5)
Temporally Serious TEAE Related to IP0000
Temporally Non-Serious TEAE Related to IP00050
SecondaryNumber of Events With Suspected Adverse Reactions or Serious and Non-Serious Adverse Reactions (ARs)

An Adverse Reactions (ARs) plus suspected adverse reaction is any adverse event which met any of the following criteria: an adverse event that began during infusion or within 72 hours following the end of IP infusion; an adverse event considered by either the investigator and/or the sponsor to be possibly or probably related to IP administration; an adverse event for which causality assessment was missing or indeterminate. Adverse reaction included both serious and non-serious ARs.

Time frame:
From start of study treatment up to early termination of the study (approximately 22 months)
Reported as:
Number · Events
Number of Events With Suspected Adverse Reactions or Serious and Non-Serious Adverse Reactions (ARs)
EventsARALAST NP 60 mg/kg (Group 1)GLASSIA 60 mg/kg (Group 3)GLASSIA 120 mg/kg (Group 4)Placebo (Group 5)
Suspected ARs or Non-serious ARs10024
Suspected ARs or Serious ARs0000
SecondaryPercentage of Participants With Suspected Adverse Reactions or Serious and Non-Serious Adverse Reactions (ARs)

An Adverse Reactions (AR) plus suspected adverse reaction is any adverse event which met any of the following criteria: an adverse event that began during infusion or within 72 hours following the end of IP infusion; an adverse event considered by either the investigator and/or the sponsor to be possibly or probably related to IP administration; an adverse event for which causality assessment was missing or indeterminate. Adverse reaction included both serious and non-serious ARs.

Time frame:
From start of study treatment up to early termination of the study (approximately 22 months)
Reported as:
Number · Percentage of Participants
Percentage of Participants With Suspected Adverse Reactions or Serious and Non-Serious Adverse Reactions (ARs)
Percentage of ParticipantsARALAST NP 60 mg/kg (Group 1)GLASSIA 60 mg/kg (Group 3)GLASSIA 120 mg/kg (Group 4)Placebo (Group 5)
Suspected ARs or Non-serious ARs1000050
Suspected ARs or Serious ARs0000
SecondaryPercentage of Participants With at Least One Infusion Rate Change or Infusion Interruption or Stopped Due to AEs

An Adverse event (AE) was defined as any untoward medical occurrence in a participant administered an IP that does not necessarily have a causal relationship with the treatment. Number of infusions for which the infusion rate was reduced and/or the infusion interrupted or stopped due to adverse events (AEs) were reported.

Time frame:
From start of study treatment up to early termination of the study (approximately 22 months)
Reported as:
Number · Percentage of Participants
Percentage of Participants With at Least One Infusion Rate Change or Infusion Interruption or Stopped Due to AEs
Percentage of ParticipantsARALAST NP 60 mg/kg (Group 1)GLASSIA 60 mg/kg (Group 3)GLASSIA 120 mg/kg (Group 4)Placebo (Group 5)
Participants with at Least 1 Infusion Rate Change00050
Participantswith at Least 1 Infusion Interruption00050
SecondaryNumber of Participants Who Developed Anti-A1PI Antibodies Following Treatment With ARALAST NP or GLASSIA

Number of participants who developed anti- A1PI antibodies following treatment with ARALAST NP or GLASSIA were reported. Anti-A1PI binding antibody were determined for the samples that tested positive or negative at each assessment time point.

Time frame:
Baseline, Early termination of the study (approximately 22 months)
Reported as:
Count of participants · Participants
Number of Participants Who Developed Anti-A1PI Antibodies Following Treatment With ARALAST NP or GLASSIA
ParticipantsARALAST NP 60 mg/kg (Group 1)GLASSIA 60 mg/kg (Group 3)GLASSIA 120 mg/kg (Group 4)Placebo (Group 5)
Number of Participants Who Developed Anti-A1PI Antibodies Following Treatment With ARALAST NP or GLASSIA0000

Adverse events

Collected over From start of study treatment up to early termination of the study (approximately 22 months). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ARALAST NP 60 mg/kg (Group 1)0/1 (0%)0/1 (0%)1/1 (100%)
ARALAST NP 120 mg/kg (Group 2)———
GLASSIA 60 mg/kg (Group 3)0/1 (0%)0/1 (0%)0/1 (0%)
GLASSIA 120 mg/kg (Group 4)0/1 (0%)0/1 (0%)0/1 (0%)
Placebo (Group 5)0/2 (0%)0/2 (0%)2/2 (100%)
Most frequent other events
Most frequent other events
EventARALAST NP 60 mg/kg (Group 1)ARALAST NP 120 mg/kg (Group 2)GLASSIA 60 mg/kg (Group 3)GLASSIA 120 mg/kg (Group 4)Placebo (Group 5)
Right Eye Retinal DetachmentEye disorders1/1—0/10/10/2
DIARRHOEAGastrointestinal disorders1/1—0/10/10/2
HeadacheNervous system disorders0/1—0/10/11/2
NauseaNervous system disorders0/1—0/10/11/2
CONTACT DERMATITISSkin and subcutaneous tissue disorders0/1—0/10/11/2
site conditions/ Catheter site rash/ MILD RASH AT THE SITE OF TAPE USED AT IV CANNULA SITEGeneral disorders0/1—0/10/11/2
Vaginal haemorrhage/ PER VAGINAL BLEEDINGReproductive system and breast disorders0/1—0/10/11/2
Chronic obstructive pulmonary disease/ COPD EXACERBATIONRespiratory, thoracic and mediastinal disorders0/1—0/10/11/2

Baseline characteristics

Safety Analysis Set (SAS) included all participants who had received any amount of investigational product (IP) or placebo, regardless of protocol deviations or non-adherence to the study procedures. Analysis was performed according to the treatment regimen received regardless of the randomized treatment regimen.

Age, Continuous
Age, Continuous(Years)ARALAST NP 60 mg/kg (Group 1)ARALAST NP 120 mg/kg (Group 2)GLASSIA 60 mg/kg (Group 3)GLASSIA 120 mg/kg (Group 4)Placebo (Group 5)Total
Mean62.0 ± NA—65.0 ± NA68.0 ± NA46.0 ± 4.2457.4 ± 10.83
Sex: Female, Male
Sex: Female, Male(Participants)ARALAST NP 60 mg/kg (Group 1)ARALAST NP 120 mg/kg (Group 2)GLASSIA 60 mg/kg (Group 3)GLASSIA 120 mg/kg (Group 4)Placebo (Group 5)Total
Female1—1125
Male0—0000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)ARALAST NP 60 mg/kg (Group 1)ARALAST NP 120 mg/kg (Group 2)GLASSIA 60 mg/kg (Group 3)GLASSIA 120 mg/kg (Group 4)Placebo (Group 5)Total
Hispanic or Latino0—0000
Not Hispanic or Latino1—1125
Unknown or Not Reported0—0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)ARALAST NP 60 mg/kg (Group 1)ARALAST NP 120 mg/kg (Group 2)GLASSIA 60 mg/kg (Group 3)GLASSIA 120 mg/kg (Group 4)Placebo (Group 5)Total
American Indian or Alaska Native0—0000
Asian0—0000
Native Hawaiian or Other Pacific Islander0—0000
Black or African American0—0000
White1—1125
More than one race0—0000
Unknown or Not Reported0—0000
08

Study locations

17 sites
  • Phoenix Medical Research Institute, LLC
    Peoria, Arizona 85381, United States
  • Newport Native MD, Inc
    Newport Beach, California 92663, United States
  • Pulmonary Disease Specialists, P.A., / PDS Research
    Kissimmee, Florida 34741, United States
  • L&C Professional Medical Research Institute
    Miami, Florida 33144, United States
  • Loyola University Health System
    Maywood, Illinois 60153, United States
  • Indiana University Health
    Indianapolis, Indiana 46202, United States
  • La Porte County Institute for Clinical Research, Inc.
    Michigan City, Indiana 46360, United States
  • Pulmonary Health Physicians
    Fayetteville, New York 13066, United States
  • Clinical Research of Gastonia
    Gastonia, North Carolina 28054, United States
  • Southeastern Research Center LLC
    Winston-Salem, North Carolina 27103, United States
  • Metroplex Pulmonary and Sleep Center
    Allen, Texas 75013, United States
  • Houston Pulmonary and Sleep Associates
    Houston, Texas 77065, United States
  • Element Research Group
    San Antonio, Texas 78258, United States
  • Renovatio Clinical-Respiratory & Sleep Disorders Specialists
    The Woodlands, Texas 77005, United States
  • St Vincent's Hospital Melbourne
    Fitzroy, Victoria 34741, Australia
  • LHSC - Victoria Hospital
    London, Ontario N6A 5W9, Canada
  • Inspiration Research Limited
    Toronto, Ontario M5T 3A9, Canada
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — De-identified individual participant data from this particular study will not be shared as there is a reasonable likelihood that individual patients could be re-identified (due to the limited number of study participants).

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2016 to primary completion in Sep 2018, 22 months.

Results were first posted in Oct 2019, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 23, 2016
First posted
Mar 30, 2016
StartActual
Nov 2, 2016
Primary completionActual
Sep 14, 2018
CompletionActual
Sep 14, 2018
Results first posted
Oct 8, 2019
Last update
May 13, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 13, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02722304
Collaborators
Baxalta Innovations GmbH, now part of Shire
Responsible party
Sponsor
First posted
Mar 30, 2016
Start date
Nov 2, 2016
Primary completion
Sep 14, 2018
Completion
Sep 14, 2018
Results posted
Oct 8, 2019
Last update
May 13, 2021

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Alpha 1-Antitrypsin

Start the discussion